Works matching IS 15257304 AND DT 2025 AND VI 26 AND IP 2


Results: 10
    1
    2
    3

    A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 2, p. 146, doi. 10.1016/j.cllc.2024.09.003
    By:
    • Spicer, J.;
    • Blais, N.;
    • Owen, S.;
    • Robinson, A. G.;
    • Chu, Q.;
    • Labbe, C.;
    • Shieh, B.;
    • Brown-Walker, P.;
    • Sederias, J.;
    • Jensen, K.;
    • Farago, A. F.;
    • Tsao, M.-S.;
    • Cottrell, T. R.;
    • Kidane, B.;
    • Laurie, S.;
    • Juergens, R.;
    • Bradbury, P. A.;
    • Tu, W.;
    • Gaudreau, P.-O.
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo) Radiotherapy.

    Published in:
    Clinical Lung Cancer, 2025, v. 26, n. 2, p. 93, doi. 10.1016/j.cllc.2024.11.003
    By:
    • Evin, Cécile;
    • Razakamanantsoa, Léo;
    • Gardavaud, François;
    • Papillon, Léa;
    • Boulaala, Hamza;
    • Ferrer, Loïc;
    • Gallinato, Olivier;
    • Colin, Thierry;
    • Ben Moussa, Sondos;
    • Harfouch, Yara;
    • Foulquier, Jean-Noël;
    • Guillerm, Sophie;
    • Bibault, Jean-Emmanuel;
    • Huguet, Florence;
    • Wagner, Mathilde;
    • Rivin del Campo, Eleonor
    Publication type:
    Article
    10